Washington, D.C. 20549

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 31, 2024
Revance Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation)(Commission File No.)(I.R.S. Employer Identification No.)
1222 Demonbreun Street, Suite 2000, Nashville, Tennessee, 37203
(Address of principal executive offices and zip code)

(615) 724-7755
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 par valueRVNCNasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨


(e) Compensatory Arrangements of Principal Executive Officer, Principal Financial Officer and Named Executive Officers

2024 Bonus Program Information

On January 31, 2024, the Compensation Committee (the “Committee”) of the Board of Directors of Revance Therapeutics, Inc. (the “Company”) approved the following components of the 2024 Bonus Program and equity mix for the Company’s executive officers. The cash bonus for the Company’s Chief Executive Officer, Mark Foley, will be based on the achievement of the 2024 corporate goals (100% weighting). For each of the other executive officers, the bonus will be based on achievement of corporate goals, subject to a modifier for individual performance that may increase or decrease the total bonus payout. An executive officer’s actual bonuses for fiscal year 2024 may exceed 100% of the executive’s 2024 target bonus percentage in the event performance exceeds the predetermined goals and/or upon the achievement of other specified goals, including stretch goals, or due to individual performance (other than for Mr. Foley). Payment of bonuses to the Company’s executive officers under the 2024 Bonus Program and the actual amount of such bonus, if any, are at the discretion of the Committee.

Target performance bonus percentages for fiscal year 2024 for the Company’s named executive officers are set forth below and expressed as a percentage of the corresponding 2024 annual base salary.

Name2024 Target Bonus Percentage
Mark J. Foley
Chief Executive Officer
Tobin C. Schilke
Chief Financial Officer
Dwight Moxie
Senior Vice President, General Counsel & Corporate Secretary

The Committee also approved 2024 target equity award values and award mix for the named executive officers. Mr. Foley’s target equity award mix will be comprised 100% of performance stock units. All other named executive officers’ target equity award mix will be split evenly between performance stock units and restricted stock units.

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:February 6, 2024Revance Therapeutics, Inc.
By:/s/ Tobin C. Schilke
Tobin C. Schilke
Chief Financial Officer

Cover Page Document
Jan. 31, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jan. 31, 2024
Entity Registrant Name Revance Therapeutics, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-36297
Entity Tax Identification Number 77-0551645
Entity Address, Address Line One 1222 Demonbreun Street, Suite 2000
Entity Address, City or Town Nashville
Entity Address, State or Province TN
Entity Address, Postal Zip Code 37203
City Area Code 615
Local Phone Number 724-7755
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol RVNC
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001479290
Amendment Flag false

Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Revance Therapeutics Charts.
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Revance Therapeutics Charts.